Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06299683 · ClinicalTrials.gov registry record · NA

Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment

A NA study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
220
Enrollment target
1
Study location

NCT06299683: Recruiting NA study of Interstitial Cystitis and Bladder Pain Syndrome, sponsored by Vanderbilt University Medical Center.

NCT06299683 is a NA study of Interstitial Cystitis and Bladder Pain Syndrome that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 220 participants, below the 354-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06299683, a NA study of Interstitial Cystitis and Bladder Pain Syndrome, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
220 participants
Enrollment target
1
Study location

Study Summary

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC/BPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently to treatment. Individuals with IC/BPS have distinct subgroups, or "phenotypes," largely characterized by the distribution of pain throughout the body. Supported by our preliminary evidence, the overall goal of this project is to assess how IC/BPS phenotype may affect response to two different therapies often given without regard to patient phenotype, pelvic floor physical therapy (PT) and cognitive-behavioral therapy (CBT) for IC/BPS.

Primary Outcome

GRA provides a global index used to rate the response of a condition to an intervention. The GRA is a 7-point centered scale that assesses patient impression of change in IC/BPS symptoms since entering the study ranging from 7= "very much worse" to 1= "very much improved." This scale will be administered at post-treatment and at follow-up. Global improvement is a core domain recommended for conducting clinical trials of the efficacy and effectiveness of treatments for chronic pain according to I

Interventions

  • BEHAVIORAL Psychosocial Treatment
  • OTHER Pelvic Floor Physical Therapy

Study Locations (1)

Tennessee

  • Vanderbilt Urology Cool Springs - Franklin

Trial Details

FieldValue
Enrollment Target 220 participants
Start Date 2024-05-01
Est. Completion 2028-04-04
Phase NA

What NCT06299683 shows while recruiting

NCT06299683 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 354-participant average among 26 other Interstitial Cystitis trials with a reported enrollment target (38% lower).

The record links to 10 conditions, with Interstitial Cystitis appearing as the primary indexed condition, and to 2 interventions - of which Psychosocial Treatment is the first listed.

NCT06299683 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT06299683 about?

NCT06299683 is a clinical study titled "Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment". Interstitial cystitis/bladder pain syndrome (IC/BPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC/BPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently t...

What is the current status of trial NCT06299683?

This trial is currently recruiting. It is a NA study. The enrollment target is 220 participants. The study started on 2024-05-01. Estimated completion is 2028-04-04.

What conditions does trial NCT06299683 study?

This clinical trial studies the following conditions: Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis, Chronic Prostatitis.

What interventions are being tested in trial NCT06299683?

The interventions under investigation include: Psychosocial Treatment (BEHAVIORAL), Pelvic Floor Physical Therapy (OTHER).

Who is sponsoring clinical trial NCT06299683?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06299683 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Interstitial Cystitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06299683's enrollment target sits among peer trials

220 8th of 26 higher than 19 of 26 other Interstitial Cystitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Interstitial Cystitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00920972 · 220 participants · Phase 1

    Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases

  • NCT01851642 · 220 participants

    Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs

  • NCT02582021 · 220 participants

    WISE CVD - Continuation (WISE HFpEF)

  • NCT04067830 · 220 participants · Phase 2

    Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06299683, the US trial registry maintained by the National Library of Medicine. NCT06299683 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.